×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NCNA – nucana plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NCNA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/5
08:00 am
ncna
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
Medium
Report
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
10/18
08:11 am
ncna
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 [Yahoo! Finance]
Low
Report
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 [Yahoo! Finance]
10/18
08:00 am
ncna
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
Low
Report
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
10/14
08:00 am
ncna
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
Low
Report
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
9/29
05:31 pm
ncna
DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsight
High
Report
DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsight
9/29
05:31 pm
ncna
DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsight
High
Report
DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsight
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/5
08:12 am
ncna
Form 6-K NuCana plc For: Nov 05
Medium
Report
Form 6-K NuCana plc For: Nov 05
10/20
08:00 am
ncna
Form 6-K NuCana plc For: Oct 20
Medium
Report
Form 6-K NuCana plc For: Oct 20
10/14
08:16 am
ncna
Form 6-K NuCana plc For: Oct 14
Low
Report
Form 6-K NuCana plc For: Oct 14
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/20
Form 6-K NuCana plc For: Aug 20
37.5%
3/4 NuCana PLC (NASDAQ: NCNA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.75 price target on the stock. 13.3%
10/25 NuCana PLC (NASDAQ: NCNA) had its "buy" rating re-affirmed by analysts at Cowen Inc. 8.7%
1/16 Form SC 13G/A NuCana plc Filed by: Morningside Venture Investments Ltd 8.3%
11/15 NuCana PLC (NASDAQ: NCNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock, down previously from $20.00. 7.9%
1/27 NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer 7.6%
8/29 NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference 7.5%
6/27 Form 6-K NuCana plc For: Jun 27 6.0%
8/19 NuCana PLC (NASDAQ: NCNA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 5.3%
11/26 NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference 5.2%
3/4 NuCana PLC (NASDAQ: NCNA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.75 price target on the stock. 13.3%
10/25 NuCana PLC (NASDAQ: NCNA) had its "buy" rating re-affirmed by analysts at Cowen Inc. 8.7%
1/16 Form SC 13G/A NuCana plc Filed by: Morningside Venture Investments Ltd 8.3%
11/15 NuCana PLC (NASDAQ: NCNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock, down previously from $20.00. 7.9%
1/27 NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer 7.6%
8/29 NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference 7.5%
6/27 Form 6-K NuCana plc For: Jun 27 6.0%
8/19 NuCana PLC (NASDAQ: NCNA) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 5.3%
11/26 NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference 5.2%
TOP News Decliners
3/10
Form 20-F NuCana plc For: Dec 31
-15.5%
5/30 NuCana to Present at the Jefferies 2019 Healthcare Conference -14.5%
3/5 NuCana PLC (NASDAQ: NCNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.2%
1/21 NuCana PLC (NASDAQ: NCNA) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.2%
12/27 Form 6-K NuCana plc For: Dec 27 -8.9%
6/26 NuCana PLC (NASDAQ: NCNA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
2/25 NuCana to Present at the Cowen and Company 40th Annual Health Care Conference -7.2%
11/12 NuCana PLC (NASDAQ: NCNA) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -6.9%
2/14 Form SC 13G/A NuCana plc Filed by: WOOD CHRISTOPHER B -5.7%
5/8 NuCana PLC (NASDAQ: NCNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
5/30 NuCana to Present at the Jefferies 2019 Healthcare Conference -14.5%
3/5 NuCana PLC (NASDAQ: NCNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.2%
1/21 NuCana PLC (NASDAQ: NCNA) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -9.2%
12/27 Form 6-K NuCana plc For: Dec 27 -8.9%
6/26 NuCana PLC (NASDAQ: NCNA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.3%
2/25 NuCana to Present at the Cowen and Company 40th Annual Health Care Conference -7.2%
11/12 NuCana PLC (NASDAQ: NCNA) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. -6.9%
2/14 Form SC 13G/A NuCana plc Filed by: WOOD CHRISTOPHER B -5.7%
5/8 NuCana PLC (NASDAQ: NCNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: